Share
Being part of the ASX will provide access to greater capital. They are also a larger investment pool of insto investors. You can imagine many people in the investment market will see this as promising.
Nasdax in time - the market cap is not large enough yet.
granted a different company but if you look at XRO
dual listed on the ASX in 2012 (5.50)
Sole listed on the ASX 2018 (29.50)
Now $150
Nz just does not have the same pool of investment capital and more companies in the bio med space.
I see this as a significant benefit in time to come.
Even self managed super (retail investors) getting access to this stock will be a good churn of the SP
